ALT The world’s first patient of the gene-editing therapy targeting APOC3 (Correctseq’s CS-121) for hyperlipidemia (the 6th from the right) has successfully completed dosing and been discharged.

ALT Specific and Efficient RNA A-to-I Editing through Cleavage of an ADAR Inhibitor

ALT Figure 1: Schematic of the RtABE working mechanism

ALT Figure 2: Comparison of editing efficacy between RtABE_V2 and MCP-ADAR2DD systems. (Left) Editing efficiencies induced by RtABE_V2 and MCP-ADAR2DD in mouse liver. (Right) Transcriptome-wide off-target counts induced by RtABE_V2 and MCP-ADAR2DD in mouse liver.

ALT Leveraging base excision repair for efficient adenine base editing of mitochondrial DNA

ALT Figure 1: Schematic of the TALED working mechanism

ALT Figure 2: Editing efficiency (top), product purity (middle), and transcriptome-wide off-target counts (bottom) mediated by sTALED, eTALED6, and eTALED6R at the m.13514 site in the mitochondrial genome

ALT A Malaysian β-thalassemia patient who received base editing therapy (Correctseq’s CS-101) in China has been transfusion-free and returned to normal life.

ALT EHA2024 Scientific Congress Report

ALT Dr. Lijie Wang, Head of Gene Editing Platform of Correctseq, gave an oral presentation at the EHA2024 Hybrid Congress

ALT The editing process of tBE (From EHA2024 Scientific Congress Report)